title: [Lung neuroendocrine large cell carcinoma in young women. An unusual presentation].
abstract: BACKGROUND
  Lung neuroendocrine large cell carcinoma is a rare tumor with a poor prognosis. There are very few guidelines for treating this cancer but a better knowledge of its markers could improve the treatment and the prognosis.
  
  
  METHODS
  We report two patients who presented initially with an early stage carcinoid tumor treated with surgery. Both patients had further new neuroendocrine disease diagnosed because of intermittent carcinoid syndrome, predominantly occurring at the same time as menstruation. They were then diagnosed with metastatic lung neuroendocrine large cell carcinoma and treated with first-line cisplatin-etoposide and second-line octreotide with estrogen plus progestin. They both had a good prognosis with no disease progression to date.
  
  
  CONCLUSIONS
  The clinical characteristics of these cases raise several questions about the pathophysiology of lung neuroendocrine large cell carcinoma and may suggest potential new treatment options. The unusual clinical presentation and good prognosis may be explained either by the second-line treatment choice or by potential molecular or hormonal biomarkers. There is a need to investigate these potential biomarkers further since they could be new therapeutic targets.
authors.affiliation: Service d'oncologie multidisciplinaire et innovations thérapeutiques, Assistance publique-Hôpitaux de Marseille, Aix-Marseille université, 13000 Marseille, France.
authors.forename: A
authors.initials: A
authors.lastname: Proux
authors.affiliation: Service d'oncologie multidisciplinaire et innovations thérapeutiques, Assistance publique-Hôpitaux de Marseille, Aix-Marseille université, 13000 Marseille, France.
authors.forename: L
authors.initials: L
authors.lastname: Greillier
authors.affiliation: Service d'oncologie multidisciplinaire et innovations thérapeutiques, Assistance publique-Hôpitaux de Marseille, Aix-Marseille université, 13000 Marseille, France.
authors.forename: F
authors.initials: F
authors.lastname: Barlesi
authors.affiliation: Service d'oncologie multidisciplinaire et innovations thérapeutiques, Assistance publique-Hôpitaux de Marseille, Aix-Marseille université, 13000 Marseille, France. Electronic address: pascale.tomasini@ap-hm.fr.
authors.forename: P
authors.initials: P
authors.lastname: Tomasini
mesh_terms: D000328:Adult; D000367:Age Factors; D002276:Carcinoid Tumor / Q000175:diagnosis / Q000473:pathology; D018287:Carcinoma, Large Cell / Q000175:diagnosis* / Q000473:pathology; D018278:Carcinoma, Neuroendocrine / Q000175:diagnosis* / Q000473:pathology; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000473:pathology; D008303:Malignant Carcinoid Syndrome / Q000175:diagnosis / Q000473:pathology; D055815:Young Adult
keywords: Biomarkers; Biomarqueurs; Cancer neuroendocrine pulmonaire; Hormone receptors; Lung carcinoid neoplasms; Lung neuroendocrine carcinoma; Octreotide; Octréotide; Récepteurs hormonaux; Tumeur carcinoïde pulmonaire